Complement-Based Drug Development Summit leaderboard
  • Tuesday, October 6, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 50

Insilico, CMS Partner on AI Drug Discovery Programs

Feb 12, 2026
Clinical-stage biotechnology company Insilico Medicine and pharmaceutical commercialization group China Medical System Holdings have announced a multi-project collaboration aimed at…
Read More...

FDA Declines Review of Moderna mRNA Flu Vaccine Filing

Feb 12, 2026
Biotechnology company Moderna, Inc. said the FDA Center for Biologics Evaluation and Research has refused to begin reviewing its biologics license application for the investigational…
Read More...

Moderna Signs Mexico Pact for Local mRNA Vaccine Production

Feb 12, 2026
Biotechnology company Moderna, Inc. has signed a five-year strategic memorandum of understanding with the Government of Mexico, state manufacturer BIRMEX and pharmaceutical firm…
Read More...

The 5th LNP Summit: Featuring End-to-End Tracks, Pre-Conference Workshops and Team Discounts

Feb 12, 2026
The 5th LNP Summit, the only industry-led forum dedicated exclusively to end-to-end LNP development, is celebrating 5 years of running the flagship event. Bringing together leaders…
Read More...

Takeda Partners With Iambic to Accelerate AI Drug Discovery

Feb 11, 2026
Takeda has entered a multi-year collaboration with clinical-stage biotechnology company Iambic aimed at accelerating the development of new medicines using artificial…
Read More...

FDA Grants Priority Review to Takeda Narcolepsy Drug

Feb 11, 2026
Takeda has taken a major step toward introducing a novel treatment for narcolepsy type 1 after the U.S. Food and Drug Administration accepted its New Drug Application and granted…
Read More...

FDA Rejects REGENXBIO Gene Therapy for Hunter Syndrome

Feb 11, 2026
REGENXBIO Inc. has received a setback in its efforts to bring a gene therapy to patients with Hunter syndrome, after the U.S. Food and Drug Administration (FDA) issued a Complete…
Read More...

Biocodex, THX Pharma Partner on Rare Disease Therapies

Feb 11, 2026
Biocodex and THX Pharma (Theranexus) have entered a strategic licensing agreement aimed at advancing treatments for three rare and serious genetic disorders, marking a significant…
Read More...

Measuring Impact in Medical Affairs Summit: Redefining How Medical Affairs Can Demonstrate its…

Feb 11, 2026
As Medical Affairs continues to evolve into a strategic cornerstone of the biopharma industry, the ability to clearly define, measure, and communicate impact has never been more…
Read More...

Everest Medicines Licenses Novel Kidney Disease Drug MT1013

Feb 6, 2026
Everest Medicines has entered an exclusive licensing agreement with Shaanxi Micot Pharmaceutical Technology to commercialize the experimental therapy MT1013 across China and the…
Read More...
Previous 1 … 48 49 50 51 52 … 956 Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
  • Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
  • CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery
  • SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing
  • AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.